Revised Outlook: Theratechnologies and AngioDynamics Fall Short
- July 12th, 2023
- 214 views
Theratechnologies Inc. (Nasdaq: THTX) reported second-quarter fiscal 2023 revenue of $17.549 million, falling short of the consensus estimate of $20.32 million. The company attributes this lower-than-expected revenue to specialty pharmacy inventory adjustments that affected its consolidated revenue.
In light of the Q2 results, Theratechnologies has revised its full-year fiscal 2023 revenue guidance range to $82 million to $87 million, compared to the consensus estimate of $91.66 million.
In pre-market, $THTX is currently trading at $0.92, reflecting a decrease of $0.05 (5.07%).
In other news, AngioDynamics, Inc. (Nasdaq: ANGO) reported fourth-quarter fiscal 2023 earnings per share (EPS) of $0.02, in line with the consensus estimate.
Looking ahead, the company anticipates an adjusted loss per share for the full-year fiscal 2024, ranging from $0.28 to $0.34, contrasting with the consensus estimate of a loss of $0.02 per share.
$ANGO is currently trading at $9.75 in pre-market, down $0.19 (1.91%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Earnings Preview: Walt Disney, Applied Materials, and Celcuity Take Center Stage
November 11th, 2024Key Metrics: CyberArk Software, Hudbay Minerals, and Sonos Earnings Due
November 11th, 2024Earnings: What to Expect from Occidental Petroleum, Rocket Lab, and CAE
November 10th, 2024Earnings Countdown: Home Depot, Sea Limited, and Natera in the Spotlight
November 10th, 2024Ahead of Earnings: DoorDash, MetLife, and Exelon in the Spotlight
October 27th, 2024
Member Login